Prelude Capital Management, LLC Mersana Therapeutics, Inc. Transaction History

Prelude Capital Management, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 16, 2021	SELL	$16.84 - $27.59 $7,409 - $12,139	-440 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$16.2 - $25.7 $7,128 - $11,308	440 New	440 $8,000
Q2 2018 Aug 14, 2018	SELL	$14.2 - $22.68 $32,092 - $51,256	-2,260 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$13.56 - $18.48 $29,370 - $40,027	2,166 Added 2304.26%	2,260 $36,000
Q4 2017 Feb 14, 2018	BUY	$14.95 - $19.9 $1,405 - $1,870	94	94 $2,000

124

114M

73.5K

46.4K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $206M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.